Kirk Lercher, MD
Brain Injury Medicine · New York, NYNPI 1346401726
Payments from drug & device makers
Across 53 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$465
- Merz North America, Inc.$245
- Merz Pharmaceuticals, LLC$134
- Azurity Pharmaceuticals, Inc.$98
- Argenx US, Inc.$70
- Ipsen Biopharmaceuticals, Inc$60
- plus $151 from 7 others
What the payments were for
- Food & beverage$1,223100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $465 |
| Merz North America, Inc. | 5 | $245 |
| Merz Pharmaceuticals, LLC | 7 | $134 |
| Azurity Pharmaceuticals, Inc. | 6 | $98 |
| Argenx US, Inc. | 4 | $70 |
| Ipsen Biopharmaceuticals, Inc | 1 | $60 |
| Amgen | 2 | $35 |
| Bioventus LLC | 1 | $29 |
| Coloplast | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few brain injury medicine providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 24 | $13,749 |
| Atorvastatin Calcium | 72 | $807 |
| Levetiracetam | 28 | $432 |
| Tamsulosin Hcl | 27 | $225 |
| Pantoprazole Sodium | 19 | $192 |
| Metoprolol Tartrate | 30 | $177 |
| ClopidogrelClopidogrel Bisulfate | 16 | $154 |
| Gabapentin | 17 | $121 |
| Famotidine | 29 | $117 |
| Losartan Potassium | 21 | $104 |
| Amlodipine Besylate | 26 | $100 |
| Carvedilol | 13 | $84 |
| Levothyroxine Sodium | 12 | $71 |
| Metoprolol Succinate | 11 | $65 |
| Metformin Hcl | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other brain injury medicine in New York
- Jaskiran GhumanNew York$8K
- Jason EdwardsNew York$986
- Michael ChiouSchenectady$239
- Sharon BushiWhite Plains$63
- Sarah KhanGlen Cove$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.